Precision Editing of Cyclophilin a to Engineer Cyclosporine- and Voclosporin- Resistant Human CAR-T Cells (ACR Convergence 2024) - Sep 25, 2024 - Abstract #0010; Pres time: Nov 16, 2024; 10:30 AM - 12:30 PM; Location: Hall C; In Person; "We edited PPIA to produce CAR-T cells resistant to CsA and VCS. This genetic modification may enable allogeneic CAR-T cells to be compatible with CNIs, a benefit for patients such as those with lupus nephritis being treated with CNIs, and as part of a strategy to help evade allogeneic CAR-T cell rejection. Engineering allogeneic products to function in the setting of different background immunomodulating therapies has the potential to expand the clinical scenarios in which CAR-T cells can be used in patients with autoimmune disease."
CAR T-Cell Therapy • IO biomarker • Glomerulonephritis • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology • CD4 • PPIA
|
|
Holly Wobma1; Francesca Alvarez-Calderon2; Jiayi Dong2; Alexandre Albanese2; Kayleigh Omdahl2; Rene Bermea3; Gillian Selig4; Marlana Winschel2; Elisa Rojas Palato2; Katherine Michaelis1; Xianliang Rui2; Bruce Blazar5; Susan Prockop2; Victor Tkachev3; Ulrike Gerdemann2; Leslie Kean2
|